Page 8 - Kalvista Board News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kalvista board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kalvista Board Today - Breaking & Trending Today

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program

First preclinical data presented for structurally diverse oral Factor XIIa inhibitors - Additional Sebetralstat data also presented - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage ....

Xiia Fxiia , Edward Feener , Jarrod Aldom , Sally Hampton , Andrew Crockett , Exchange Commission , Development Officer , Kalvista Pharmaceuticals Inc , Vp Research , Corporate Communications , Vista Pharmaceuticals , Chief Executive Officer , Kallikrein Kinin System , Kinin System , Chief Scientific Officer , Oral Inhibitors , Chris Yea , Chief Development , Kalvista Pharmaceuticals , Looking Statements , Securities Litigation Reform Act ,

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today ....

Jarrod Aldom , Exchange Commission , Kalvista Pharmaceuticals Inc , Corporate Communications , Kalvista Pharmaceuticals , Annual Jefferies Global Healthcare Conference , Vista Pharmaceuticals , Securities Litigation Reform Act ,

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Changes to Board of Directors

- Patrick A. Treanor Appointed Effective Immediately - - Dan Soland Resigns in Planned Transition - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused ....

Patricka Treanor , Vifor Pharma , Jarrod Aldom , Pathalys Pharma , Dan Soland , Andrew Crockett , Company Board Of Directors , Oscient Pharmaceuticals , Bryant University , Rensselaer Polytechnic Institute , Insulet Corporation , Exchange Commission , Kalvista Pharmaceuticals Inc , Corporate Communications , Abbott Labs , Appointed Effective Immediately , Soland Resigns , Planned Transition , Vista Pharmaceuticals , Chief Operating Officer , Chief Executive Officer , Kalvista Pharmaceuticals , Securities Litigation Reform Act ,

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900

- "Sebetralstat" Approved by WHO and USAN - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral ....

United States , Jarrod Aldom , Andrew Crockett , Exchange Commission , Kalvista Pharmaceuticals Inc , World Health Organization International Nonproprietary Names , Corporate Communications , American Medical Association United States Adopted Names , Expert Committee , Vista Pharmaceuticals , World Health Organization , International Nonproprietary Names , American Medical Association , United States Adopted Names , Chief Executive Officer , Kalvista Pharmaceuticals , Looking Statements , Securities Litigation Reform Act ,

KalVista Pharmaceuticals, Inc.: KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today ....

United Kingdom , Andrew Crockett , Ben Palleiko , Exchange Commission , British Society For Allergy Clinical Immunology , Kalvista Pharmaceuticals Inc , Kalvista Pharmaceuticals , Clinical Experimental Allergy , Chief Executive Officer , Experimental Allergy , British Society , Allergy Clinical , Vista Pharmaceuticals , Looking Statements , Securities Litigation Reform Act ,